Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma
This study aims to evaluate the efficacy and safety of a three drug combination therapy of aponermin, pomalidomide, and dexamethasone in the treatment of relapsed or refractory multiple myeloma
Multiple Myeloma, Neoplasms
DRUG: Aponermin, pomalidomide, dexamethasone
Overall Response, Overall haematological response after 4 cycles of treatments, 4 months
PFS, Progression free survival, from initiation of Apo-Pd treatment to the occurrence of disease progression or death, 2 years|Adverse events, To determine safety of aponermin, pomalidomide and dexamethasone for the treatment of relapsed and refractory multiple myeloma, 2 years
This study aims to evaluate the efficacy and safety of a three drug combination therapy of aponermin, pomalidomide, and dexamethasone in the treatment of relapsed or refractory multiple myeloma